Prostate Cancer
Drug design must account for prostate cancer cell progress to refractory state
Published in Blood Weekly, June 9th, 2005
"Prostate cancers are genetically and phenotypically heterogenous. The heterogeneous nature of prostate cancer may be a consequence of mutations in different cell types (basal stem, transit amplifying or luminal cells) resulting in different malignant maturation pathways.
"One consistent characterization of these cancers, however, is their eventual progression to a hormonal refractory state," scientists in the United States report.
"The development of effective novel therapeutic strategies requires an understanding of the mechanisms...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-06-09)
More Articles from Blood Weekly
- Diagnostics
High-throughput analysis detects genomic DNA in blood at a rapid pace - Embryonic Stem Cell Research
More embryos reach blastocyte stage in vitro without leukemia inhibitory factor - Neural Stem Cell Research
Intraspinal NSC graft improves motor recovery/causes aberrant axonal sprouting - Stem Cell Transplantation
p53 gene deletion adverse prognostic factor in multiple myeloma after ASCT - Tissue Engineering
T2 mapping permits evaluation of cartilage repair after biomaterial implantation - Acute Lymphoblastic Leukemia
Company initiates phase I/II clinical trial of talotrexin in patients with ALL - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
